Please login to the form below

Not currently logged in
Email:
Password:

Merck & Co wins hepatitis C patent dispute with Gilead

US jury upholds claim that Sovaldi and Harvoni infringe two sofosbuvir patents

Merck & Co.A US federal court may have thrown a spanner into the workings of the hepatitis C virus (HCV) therapy market after siding with Merck & Co in a patent dispute.

The jury in the lawsuit upheld Merck's claim that Gilead's sofosbuvir - which features in its massive-selling Sovaldi and Harvoni HCV drugs - infringes two patents it holds alongside Ionis Pharmaceuticals (formerly known as Isis Pharma).

The consequences of the ruling remain unclear but in principle could mean that Gilead is forced to hand over to Merck a portion of Sovaldi and Harvoni sales revenues - which reached $12.5bn last year. Merck is asking for $2bn in damages and a 10% cut on all future sales of sofosbuvir-based products.

Gilead is however expected to take the case to the Court of Appeals for the Federal Circuit (CAFC) for further ruling.

Merck recently launched its own HCV therapy - Zepatier (elbasvir and grazoprevir) - in direct competition to Gilead's franchise and said in a statement that it felt the outcome "reflected the evidence in the case".

The patent dispute dates back to August 2013, when Merck first contacted Gilead requesting that the company pay royalties on sofosbuvir and obtain a license to the two patents - Nos. 7,105,499 and 8,481,712.

In the same month Gilead filed a lawsuit seeking a declaratory judgment that the Merck patents are invalid and not infringed on the basis that they "cover compounds which do not include, but may relate to, sofosbuvir".

Gilead alleged in the lawsuit that Merck had amended its patent application in an attempt to extend its coverage to include sofosbuvir.

Gilead is also in the throes of a lawsuit with AbbVie, which claims it holds patents infringed by Harvoni. Gilead filed to invalidate the patents in December 2013.

Meanwhile, several groups have filed opposition to Gilead's European patents for sofosbuvir that expires in 2028.

Article by
Phil Taylor

24th March 2016

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Origins Insights

Our goal is to identify and embed transformational patient insights as a fundamental part of the drug development process. As...

Latest intelligence

Personalised medicine: driving a need for greater diversity in clinical trials
Kate Shaw, Innovative Trials' Founder & CEO, investigates one of the biggest challenges facing clinical research today....
Congresses and conferences
Superstar congresses and conferences will stay centre stage but now share the limelight with virtual and hybrid events
With the pandemic having dimmed the lights on pharma conferences, their virtual and hybrid replacements have grasped the opportunity and are here to stay...
Cervical Cancer Prevention Month
In this first 2022 blog, the Innovative Trials' Equality & Diversity committee will be looking at raising awareness around Cervical Cancer...